- Rigel Pharmaceuticals' (NASDAQ:RIGL) ophthalmic JAK/SYK inhibitor, R348, did not achieve its primary or secondary endpoints in a Phase 2 clinical trial in patients with dry eye disease. The endpoints were: changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo.
- The company will cease its development of R348 for dry eye disease but will continue its Phase 2 study of dry eye in patients with graft vs host disease (GvHD).
- Separately, the firm has stopped it indirect AMPK activator program, R118, due to its side-effect profile demonstrated in Phase 1. It will continue its direct AMPK activator research program.
- Shares are down 9% premarket on modest volume.
Rigal dry eye disease drug candidate fails Phase 2 trial
Recommended For You
More Trending News
About RIGL Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RIGL | - | - |
Rigel Pharmaceuticals, Inc. |